We want to understand how cancer develops and how to treat it more effectively. This requires a deeper knowledge of the ways that normal cells:
- divide
- maintain stable genomes
- regulate gene expression
We also need an understanding of how these cells are defective in cancer.
These discoveries will allow us to diagnose and treat cancer sooner and better.
We study the fundamental mechanisms relevant to cancer of:
- cell division
- genome stability
- DNA damage responses
- gene expression
We use human cells in culture and from patients, and model systems such as yeast and mice. Our work is relevant to all cancers, but has an emphasis on blood and prostate cancer.
We have discovered a number of genetic abnormalities that improve diagnosis of leukaemia. This has led to changes in the therapy given to patients.
We have identified kinases that control cell division. We have also developed inhibitors of cell cycle kinases that serve as leads for drug development.
We participated in the development of the PARP inhibitor drug Rubraca used for the treatment of ovarian cancer.
Our team
- David Elliott
- Jonathan Higgins
- Jun-yong Huang
- Christine Harrison
- Lisa Russell
- Nicola Curtin
- Sarra Ryan
- Jane Endicott
- Luke Gaughan
- Craig Robson
- Claudia Schneider
- Daniel Rico
- Ruchi Shukla
- Neil Perkins
- Ian Hickson
- Aneta Mikulasova
- Paul Sinclair
- Olaf Heidenreich
- Kelly Coffey
- Jim Allan
- Steve Clifford
.jpg)
.jpg)
.jpg)